Publications

Oncology

Joly F et al. Patient perspectives on the daily burden of prostate cancer: an online patient study. JMIR 2025; epub ahead a print (writing assistance)

Frank P et al. Experience and care pathway of patients with lung cancer: an online international survey. Oncol & Ther 2024; epub ahead a print. DOI: 10.1007/s40487-024-00314-2 (writing assistance)

Niedersuess-Beke et al. Real-world evidence for enfortumab vedotin in patients with metastatic urothelial cancer: an Austrian multicentre study. Clin Genitourinary Cancer 2024; 102278, epub ahead a print. DOI: 10.1016/j.clgc.2024.102278 (authorship)

Santagostino A et al. Challenging management of relapsed/refractory angioimmunoblastic T-cell lymphoma: insights from two complex cases with long-term response to belinostat. Ann Case Reports 2024; 9(6):2059. DOI:10.29011/2574-7754.102059 (writing assistance)

Boulmé F. EBMT congress report 2024, memo InHaematology Springer-Verlag GmbH

Wilde S et Graux C. Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T-cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: a case report. Clin Case Report 2024; 12(7):e9159. DOI: 10.1002/ccr3.9159 (writing assistance)

Boulmé F. SABCS congress report in solid tumors 2023, special memo InOncology/PharmaNews Springer-Verlag GmbH

Boulmé F. EANM congress report in solid tumors 2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/4b2LNKh)

Camus V et al. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: a case report. Clin Case Report 2023; 11(6):e7623. DOI: 10.1002/ccr3.7623 (writing assistance)

Filipits M et al. Epidermal growth factor receptor T790M mutation testing in non-small cell lung cancer: an international collaborative study to assess molecular EGFR T790M testing in liquid biopsy. Cancers 2023; 15(13):3528. DOI: 10.3390/cancers15133528 (writing assistance)

Illini O et al. Characteristics and treatment outcomes in advanced-stage non-small cell lung cancer patients with a KRAS G12C mutation: a real-world study. J Clin Med 2022; 11(14):4098. DOI: 10.3390/jcm11144098 (writing assistance)

Illini O et al. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv Med Oncol 2022;14:17588359221103206. DOI: 10.1177/17588359221103206 (writing assistance)

Boulmé F. ASCO congress report in solid tumors 2021/2022/2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/3fKeGRg)

Boulmé F. ESMO congress report in solid tumors 2021/2022/2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/3IJhdYv)

Boulmé F. ESMO-IO congress report in solid tumors 2021/2022, memo InOncology Springer-Verlag GmbH (bit.ly/3IJhdYv)

Boulmé F. ASH congress report 2020/2022, memo InHaematology Springer-Verlag GmbH

Boulmé F. iwWM congress report 2022, memo InHaematology Springer-Verlag GmbH

Hochmair MJ et al. Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report. Clin Lung Cancer 2021; S1525-7304(21)00277-1. DOI: 10.1016/j.cllc.2021.11.002 (writing assistance)

Illini O et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol 2021; 13:17588359211019675. DOI: 10.1177/17588359211019675 (writing assistance)

Boulmé F. RET as therapeutic target in NSCLC and thyroid cancer. SPECTRUM Onkologie e-news. Medahead, June 2021, in German (bit.ly/3w4txf0)

Boulmé F. RET as oncogene driver in advanced thyroid cancer. SPECTRUM Onkologie e-news. Medahead, June 2021, in German (bit.ly/3x7m5kq)

Boulmé F. CME: The sickle cell disease. Die Punkte:On, MedMedia Austria, May 2021, in German

Boulmé F. Selpercatinib in advanced RET-fusions-positive NSCLC. Case reports (in German). MedMedia, March 2021 (bit.ly/3VYSB75)

Boulmé F. CME: The new era of immunotherapy by cancer: the role of the medical practitioner. Die Punkte:On, Medizin Medien Austria, March 2021, in German (bit.ly/49XSmi9)

Hochmair MJ et al. Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anticancer Drugs 2021; 32(1):105-110. DOI: 10.1097/CAD.0000000000000989 (writing assistance)

Boulmé F. CME: Real World Evidence. CliniCum Onko, Medizin Medien Austria, September 2020, in German (bit.ly/4a1w2o8)

Boulmé F. Positionspaper: Do we need a modification of the RCC therapie during COVID-19 pandemic? Virtual experts meeting, RCC Academy, August 2020 (bit.ly/3W2rGqL)

Boulmé F. medonline: Onko News (articles in German), 2020 (bit.ly/3PgcVNh)

Boulmé F. CME: Precision Oncology. CliniCum Onko, Medizin Medien Austria, April 2020, in German (bit.ly/3BSmbnR)

Boulmé F. Lung cancer: primary cause of death. Ärzte Woche (9), Springer-Verlag, February 2020, in German

Virology

Custovic A et al. Multi-country cross-sectional survey on parents’ perception of RSV disease and subsequent wheezing burden. Pediatric allergy and immunology 2024; 35(6):e14169. DOI: 10.1111/pai.14169 (writing assistance)

Boulmé F. ECCMID 2023 congress report

Bouwensch C et al. Analysis of 160 nonhospitalized COVID-19 patients with mild to moderate symptoms from an Austrian general medical practice: from typical disease pattern to unexpected clinical features. Wiener Medizinische Wochenschrift 2022; 172(9-10):198-210. DOI: 10.1007/s10354-022-00919-0 (authorship)

LaMori J et al. Patient satisfaction with once-daily single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (DRV/c/FTC/TAF): a real-world study of patient self-reported outcomes in HIV-1-diagnosed adults. Patient Prefer Adherence 2022; 16:83-94. DOI: 10.2147/PPA.S332555 (writing assistance)

Blakemore C et al. Rapid swallow improvement following pharyngeal electrical stimulation in a COVID-19 patient with long-term severe neurogenic dysphagia: a case report. JRM-CC 2021; 4:1000073. DOI: 10.2340/20030711-1000073 (writing assistance)

Pécout C et al. Impact of the COVID-19 pandemic on patients affected by non-communicable diseases in Europe and in the USA. Int J Environ Res Public Health 2021;18(13):6697. DOI: 10.3390/ijerph18136697 (writing assistance)

M. Traugott et al. Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report. J Med Case Rep 2020; 15(1):148. DOI: 10.1186/s13256-021-02763-z (writing assistance)

Boulmé F. Recommendations for ICU care of SARS-CoV-2 positive patients. Ärzte Woche. (17), Springer-Verlag, April 2020, in German

Boulmé F. CME: SARS-CoV-2 in waiting room . Ärzte Woche (12), Springer-Verlag, March 2020, in German (bit.ly/3ZW9xfA)

Freund F et al. Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex. Nucleic Acids Res 2001; 29:2757-2765. DOI: 10.1093/nar/29.13.2757 (authorship)

Freund F et al. Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex. Antisense Nucleic Acid Drug Dev 2001; 11:301-315 DOI: 10.1089/108729001753231687 (authorship)

Litvak S et al. (2001) Reverse transcriptase of HIV-1: novel therapeutic interventions” in “Pharmacology of HIV infection and AIDS, edited by Dietmar Fuchs, OICA International Press, Saint-Lucia, London (authorship)

Boulmé F et al. Study of HIV-2 primer-template initiation complex using antisense oligonucleotides. Eur J Biochem 2000; 267:2803-2811. DOI: 10.1046/j.1432-1327.2000.01310.x

Mestre B et al. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim Biophys Acta 1999; 1445:86-98. DOI: 10.1016/s0167-4781(99)00019-6 (authorship)

Boulmé F. In vitro effect of phosphodiester and chemically modified antisense oligonucleotides on the initiation step of the HIV-1 and HIV-2 reverse transcription. PhD obtained on the 22nd of June1998, University of Bordeaux II, France.

Boulmé F et al. Modified (PNA, 2’O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res 1998; 26:5492-5500. DOI: 10.1093/nar/26.23.5492

Boulmé F et al. Initiation of in vitro reverse transcription from tRNALys3 on HIV-1 and HIV-2 RNAs by both type 1 and type 2 reverse transcriptases. FEBS Letters 1998; 430:165-170. DOI: 10.1016/s0014-5793(98)00649-8

Dufour E et al. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1: interactions with primer tRNALys3, initiation of cDNA synthesis and effect of inhibitors. Eur J Biochem 1998; 251:487-495. DOI: 10.1046/j.1432-1327.1998.2510487.x (authorship)

Boulmé F et al. Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Biochim Biophys Acta 1997; 1351:249-255. DOI: 10.1016/s0167-4781(97)00026-2

Dermatology

Report on annual conference ÖADF, Austrian Society for Dermatology and Venerology, SKIN International, May 2024 (bit.ly/4iWYNpQ) (in German)

Mateeva V et al. Patient with severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36 monoclonal antibody. J German Soc Derm 2024; 84(1):45-58. DOI: 10.1111/ddg.15334 (writing assistance)

Report on annual conference ÖGDV, Austrian Society for Dermatology and Venerology, SKIN International, Nov. 2023 (bit.ly/4a3qZDB) (in German)

Preibisz L et al. Barbed polydioxanone sutures for face recountouring: six-month safety and effectiveness data supported by objective markerless tracking analysis. Aesthet Surg J 2022; 42(1):NP41-NP54. DOI: 10.1093/asj/sjab359 (authorship)

Neurology

Muhle P et al. Pharyngeal electrical stimulation prior to extubation – Reduction of extubation failure rate in acute stroke patients? J Crit Care 2024; 82:154808, 82:154808. DOI: 10.1016/j.jcrc.2024.154808 (writing assistance)

Likar R et al. Management of swallowing disorders in ICU patients – a multinational expert opinion. J Crit Care 2024; 79:154447. DOI: 10.1016/j.jcrc.2023.154447 (writing assistance)

Traugott MT et al. Pharyngeal electrical stimulation treatment of critically Ill intensive care tracheostomized patients presenting with severe neurogenic dysphagia: a case series. Austin J Pulm Respir Med 2022; 9(1):1088 DOI: 10.26420/austinjpulmrespirmed.2022.1088 (writing assistance)

Traugott MT et al. Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report. J Med Case Rep 2021; 15(1):148. DOI: 10.1186/s13256-021-02763-z (writing assistance)

Beirer S et al. Therapy-resistant dysphagia successfully treated using pharyngeal electrical stimulation in a patient with the pharyngeal-cervical-brachial variant of the Guillain-Barré syndrome. eNeurologicalSci 2020; 20:100255. DOI: 10.1016/j.ensci.2020.100255 (writing assistance)

Rheumatology

Roux C et al. Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database. Joint Bone Spine 2022; 89(4):105340. DOI: 10.1016/j.jbspin.2021.105340 (writing assistance)

Diabetes

Skovlund SE et al. Identification of core outcome domains and design of a survey questionnaire to evaluate impacts of digital health solutions that matter to people with diabetes. J of Diabetes Sci and Technol 2023; 19322968231179740. DOI : 10.1177/19322968231179740 (writing assistance)

Haematology/Haemato-oncology

Boulmé F. EBMT congress report 2024, special memo InOncology, Springer-Verlag GmbH

Boulmé F. Early therapy of polycythaemia vera, also bei low risk patients. Congress report ÖHEM 2022. memo InHaematology special issue by Springer-Verlag GmbH, in German

Boulmé F. Myeloproliferative neoplasms/polycythemia Vera: perspectives in modern interferon therapy. Congress report e-IHEM 2021. memo InHaematology special issue by Springer-Verlag GmbH

Boulmé F. Diagnostic of mastocytosis. Expert meeting, May 2021, in German

Boulmé. CME: The sickle cell disease. Die Punkte:On, MedMedia Austria, May 2021, in German

Boulmé F. CME: Diagnostic of systemic mastocytosis. Die Punkte:On, MedMedia Austria, April 2021, in German (bit.ly/40eHp8K)

Pradet-Balade B et al. Massive translational repression of gene expression during mouse erythroid differentiation. Biochim Biophys Acta 2010; 1799:630-641. DOI: 10.1016/j.bbagrm.2010.08.006 (authorship)

Leberbauer C et al. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 2005; 105:85-94. DOI: 10.1182/blood-2004-03-1002 (authorship)

Joosten M et al. Translational control of putative proto-oncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling. J Biol Chem 2004; 279:38169-38176. DOI: 10.1074/jbc.M401283200 (authorship)

Dolznig H et al. Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J 2001;15,:442-1444. DOI: 10.1096/fj.00-0705fje (authorship)

Asthma

George M et al. Patients with severe uncontrolled asthma: perception of asthma control and its management. Pulm Ther 2022; 8(2): 209-222. DOI: 10.1007/s41030-022-00190-z (writing assistance)

Translation control

Pradet-Balade B, Boulmé F, Beug H, Müllner, EW et al. Translation control: bridging the gap between genomics and proteomics?Trends Biochem Sci 2001; 26:225-229. DOI: 10.1016/s0968-0004(00)01776-x (authorship)

Pradet-Balade B, Boulmé F, Müllner, EW, Garcia-Sanz JA. Reliability of mRNA profiling: verification for samples with different complexities. Biotechniques 2001; 30:1352-1357. DOI: 10.2144/01306rr03 (authorship)